Second Quarter 2023 Financial Results

August 3, 2023

Forward-looking statements and disclaimer

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: Moderna's submissions to regulators globally for the approval or authorization of mRNA-1273.815; Moderna's ability to supply mRNA-1273.815 in time for the fall 2023 season; anticipated 2023 COVID-19 sales, including the timing of sales, from existing advance purchase agreements and additional sales for delivery in the second half of 2023, which may not be realized; Moderna's expectations regarding the commercial COVID-19 market, including the U.S. fall 2023 market size, and its ability to effectively compete in such a market; the potential best-in-class profile of Moderna's RSV vaccine, including its efficacy, safety and tolerability profile; the Phase 3 study of Moderna's individualized neoantigen therapy (INT) in adjuvant melanoma; plans to expand INT to additional tumor types; timing for an update from the P303 Phase 3 study; the potential for the P303 study to enable licensure of mRNA-1010 through accelerated approval; timing for completed enrollment of the Phase 3 clinical trial of Moderna's CMV vaccine; Moderna's capital allocation priorities, including anticipated spending on R&D for 2023; Moderna's plans to launch a number of new products in 2024 through 2026, including its RSV vaccine in 2024; and Moderna's 2023 financial framework, including with respect to cost of sales. In some cases, forward-looking statements can be identified by terminology such as "will," "may," "should," "could," "expects," "intends," "plans," "aims," "anticipates," "believes," "estimates," "predicts," "potential," "continue," or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. The forward-looking statements in this presentation are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna's control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others, those risks and uncertainties described under the heading "Risk Factors" in Moderna's Annual Report on Form 10-K for the fiscal year ended December 31, 2022, filed with the U.S. Securities and Exchange Commission (SEC), and in subsequent filings made by Moderna with the SEC, which are available on the SEC's website at www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this presentation in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna's current expectations and speak only as of the date of this presentation.

Financial figures in this presentation as of, and for the quarterly periods ended, June 30, 2023, and June 30, 2022, are unaudited.

2Q23 earnings call agenda

Business Review
Stéphane Bancel, CEO

R&D/Clinical Programs
Stephen Hoge, M.D., President

Commercial Market
Arpa Garay, CCO

Financials
Jamey Mock, CFO

Looking Forward
Stéphane Bancel, CEO

2Q23 financial highlights

2Q23 GAAP financial results

Revenue:
$0.3 billion

Net income (loss):
$(1.4) billion

Earnings per share (loss):
$(3.62)

Cash and investments:
$14.6 billion

Capital allocation highlights

Reinvest in the business

- $1.1 billion R&D
- $0.3 billion SG&A
- $0.2 billion capital expenditures

External investment opportunities (licenses and/or M&A)

2023: OriCiro (renamed Moderna Enzymatics), CytomX, Life Edit, Generation Bio

Return capital to shareholders

Repurchased 4.4 million shares for $0.6 billion in 2Q23

moderna

2Q23 commercial and late-stage clinical updates

2023 COVID-19 market

- Submitted updated COVID-19 vaccine to regulators globally for approval/authorization
- Expecting full year 2023 COVID-19 sales of $6-8 billion



RSV regulatory pre-launch activity

- Rolling submission started in the United States
- Additional regulatory applications submitted in Europe, Switzerland, Australia and United Kingdom
- Started to manufacture mRNA-1345 (presentation in pre-filled syringes)

Individualized Neoantigen Therapy (INT)

- Initiated Phase 3 study in adjuvant melanoma; enrolling patients
- Scaling manufacturing to support clinical development and commercial markets

moderna

Moderna as of August 2023

Pipeline

Commercial

Moderna COVID-19 Vaccine/Spikevax®

6 in Phase 3

COVID-19 boosters, Flu, RSV, CMV, Next-generation COVID-19, INT

7 in Phase 2

Zika, PA, VEGF-A, Next-gen Flu

47 development programs

Programs in development

Respiratory vaccines

- COVID-19; next-gen COVID-19
- Older adults RSV; pediatric RSV
- Flu; next-gen flu; pandemic flu
- Flu + COVID-19, flu + COVID-19 + RSV and flu + RSV
- Next-gen combinations
- hMPV + PIV3
- RSV + hMPV, endemic HCoV

Latent vaccines

- CMV
- EBV
- HIV
- VZV
- HSV

Emerging vaccines

- Zika
- Nipah
- Norovirus
- Lyme

mRNA therapeutics

15 medicines in 4 therapeutic areas

- 5 Immuno-Oncology
- 7 Rare Diseases
- 2 Cardiovascular Diseases
- 1 Autoimmune Disease

Foundations

~5,150 employees[1]

Great Place To Work.® Officially recognized as a Great Place to Work in the U.S. by Great Place To Work®

17 commercial subsidiaries across North America, Europe and Asia Pacific

~$14.6B of cash and investments [1]

1.As of June 30, 2023

moderna

Accelerating AI at Moderna

Moderna named one of the world's most innovative companies for "pioneering AI-driven innovation"

Source: Boston Consulting Group

MODERNA MINDSET
We digitize everywhere possible using the power of digital information to maximize our impact on patients.

Use of large language models growing at Moderna



2Q23 earnings call agenda

Business Review
Stéphane Bancel, CEO

R&D/Clinical Programs
Stephen Hoge, M.D., President

Commercial Market
Arpa Garay, CCO

Financials
Jamey Mock, CFO

Looking Forward
Stéphane Bancel, CEO

Respiratory vaccines pipeline overview

Commercial and Phase 3 programs

PC | Ph. 1 | Ph. 2 | Ph. 3 | Comm.

COVID-19 (mRNA-1273.222/.815)

PC | Ph. 1 | Ph. 2 | Ph. 3 | Comm.

Older adults RSV (mRNA-1345)

PC | Ph. 1 | Ph. 2 | Ph. 3 | Comm.

Flu (mRNA-1010)

Next-gen programs

PC | Ph. 1 | Ph. 2 | Ph. 3 | Comm.

COVID-19 next-gen booster (mRNA-1283)

PC | Ph. 1 | Ph. 2 | Ph. 3 | Comm.

Flu (mRNA-1011/-1012)

PC | Ph. 1 | Ph. 2 | Ph. 3 | Comm.

Flu (mRNA-1020/-1030)

Combination programs

PC | Ph. 1 | Ph. 2 | Ph. 3 | Comm.

COVID-19 + flu (mRNA-1073/-1083)

PC | Ph. 1 | Ph. 2 | Ph. 3 | Comm.

COVID-19 + flu + RSV (mRNA-1230)

PC | Ph. 1 | Ph. 2 | Ph. 3 | Comm.

RSV + flu (mRNA-1045)

PC | Ph. 1 | Ph. 2 | Ph. 3 | Comm.

Pediatric hMPV + PIV3 (mRNA-1653)

PC | Ph. 1 | Ph. 2 | Ph. 3 | Comm.

Pediatric RSV + hMPV (mRNA-1365)

moderna

Updated XBB.1.5 COVID-19 vaccine submitted globally for regulatory approval ahead of Fall 2023 season

COVID-19 updated regulatory recommendations

- On its June 15th meeting, VRBPAC unanimously recommended a monovalent XBB lineage vaccine, with a preference for selection of XBB.1.5 expressed during discussions; similar recommendations were made by the WHO and EMA
- Following VRBPAC recommendation, FDA advised manufacturers to develop monovalent XBB.1.5 composition
- ACIP is expected to publish updated recommendations following vaccine approval/authorization

VRBPAC: Vaccines and Related Biological Products Advisory Committee
ACIP: Advisory Committee on Immunization Practices

Clinical data from our Phase 2/3 study with a monovalent XBB.1.5 vaccine (mRNA-1273.815) demonstrated potent neutralization and cross-reactivity



Moderna PSVN research assay
Subset analysis presented during June 15 VRBPAC

moderna

RSV: mRNA-1345 older adult on track for expected global regulatory approvals in 2024 with potential best-in-class profile

U.S. regulatory submission

Initiated a rolling submission process for a Biologics License Application (BLA) to the FDA, with the option to use a Priority Review Voucher (PRV)

Global regulatory submissions

Regulatory applications submitted in Europe (EMA), Switzerland (Swissmedic), Australia (TGA) and United Kingdom (MHRA)

FDA: U.S. Food and Drug Administration
EMA: European Medicines Agency
TGA: Therapeutic Goods Administration
MHRA: Medicines and Healthcare products Regulatory Agency

moderna

Flu: mRNA-1010 P303 Phase 3 study is fully enrolled; update expected in 3Q23

Design
Randomized, observer-blind, active-controlled study

Number of participants
2,400 medically stable adults ≥ 18 years old

Vaccination schedule
Randomization 1:1 to mRNA-1010 or active comparator

Duration: 6 months
Enrollment period: April –June 2023

Study participants will be followed up for 6 months after study injection

Site location
Northern Hemisphere (United States)

- **P303 will test the immunogenicity of an updated formulation of mRNA-1010**
- **Expect to share an update on P303 in 3Q23**
- **Intended to enable the licensure of mRNA-1010 through an accelerated approval**

Latent vaccines

Phase 3 CMVictory study is >80% enrolled

Phase 3 programs

PC | Ph. 1 | Ph. 2 | Ph. 3 | Comm.

CMV (mRNA-1647)

Early clinical programs

PC | Ph. 1 | Ph. 2 | Ph. 3 | Comm.

EBV (mRNA-1189; mRNA-1195)

PC | Ph. 1 | Ph. 2 | Ph. 3 | Comm.

HIV (mRNA-1644; mRNA-1574)

PC | Ph. 1 | Ph. 2 | Ph. 3 | Comm.

VZV (mRNA-1468)

Pre-clinical programs

PC | Ph. 1 | Ph. 2 | Ph. 3 | Comm.

HSV (mRNA-1608)

moderna

mRNA therapeutics

INT enrolling patients in Phase 3 adjuvant melanoma study; PA dose confirmation cohort ongoing

Immuno-oncology

PC | Ph. 1 | Ph. 2 | Ph. 3 | Comm.

Individualized Neoantigen Therapy (INT) (mRNA-4157)

PC | Ph. 1 | Ph. 2 | Ph. 3 | Comm.

Checkpoint vaccine (mRNA-4359)

PC | Ph. 1 | Ph. 2 | Ph. 3 | Comm.

Triplet (mRNA-2752)

PC | Ph. 1 | Ph. 2 | Ph. 3 | Comm.

IL-12 (MEDI1191)

PC | Ph. 1 | Ph. 2 | Ph. 3 | Comm.

KRAS (mRNA-5671)

Cardiovascular

PC | Ph. 1 | Ph. 2 | Ph. 3 | Comm.

Relaxin (mRNA-0184)

PC | Ph. 1 | Ph. 2 | Ph. 3 | Comm.

VEGF-A (AZD8601)

Autoimmune

PC | Ph. 1 | Ph. 2 | Ph. 3 | Comm.

PD-L1 (mRNA-6981)

Rare Disease

PC | Ph. 1 | Ph. 2 | Ph. 3 | Comm.

PA (mRNA-3927)

PC | Ph. 1 | Ph. 2 | Ph. 3 | Comm.

MMA (mRNA-3705)

PC | Ph. 1 | Ph. 2 | Ph. 3 | Comm.

GSD1a (mRNA-3745)

PC | Ph. 1 | Ph. 2 | Ph. 3 | Comm.

CF (VX-522)

PC | Ph. 1 | Ph. 2 | Ph. 3 | Comm.

OTC, PKU, CN-1 (mRNA-3139/-3238/-3351)

moderna

INT: adjuvant melanoma Phase 3 trial is now enrolling

Primary endpoint is recurrence free survival compared to pembrolizumab



Randomized, double-blind placebo controlled, INT + pembrolizumab (KEYTRUDA®) vs. placebo + pembrolizumab (1:1)

Resected melanoma patients: stage IIB or IIC, III, IV

Primary endpoint: recurrence free survival (RFS)

Secondary endpoints: Distant Metastasis-Free Survival (DMFS), Overall-Survival (OS)

Number of participants: ~1,089

NCT05933577

2Q23 earnings call agenda

Business Review
Stéphane Bancel, CEO

R&D/Clinical Programs
Stephen Hoge, M.D., President

Commercial Market
Arpa Garay, CCO

Financials
Jamey Mock, CFO

Looking Forward
Stéphane Bancel, CEO

2Q23 COVID-19 vaccine sales of $0.3B



Achieved expectations of ~$2B 1H23 APA deliveries

- $0.3 billion of vaccine sales from previously announced APAs were delivered in 2Q23
- $2.1 billion in vaccine sales reported in 1H23

Additional sales expected beginning in 2H23 from mRNA-1273.815 (XBB.1.5 variant) COVID-19 vaccine

Expecting 2023 COVID-19 sales of $6-8B, dependent on U.S. vaccination rates

Previously announced APAs

1H deliveries

- European Union
- Japan
- South Korea
- Other countries

$2.1B

2H deliveries

- Canada
- Kuwait
- Switzerland
- Taiwan
- United Kingdom

~$2B

(~$1B of original $3B of APAs expected to be deferred to 2024)

Expected additional sales for 2H deliveries

- United States
- Japan
- European Union
- Other markets

~$2-4B

moderna

Expecting 2023 COVID-19 sales of $6-8B, dependent on U.S. vaccination rates

Previously announced APAs

1H deliveries

- European Union
- Japan
- South Korea
- Other countries

$2.1B

2H deliveries

- Canada
- Kuwait
- Switzerland
- Taiwan
- United Kingdom

~$2B

(~$1B of original $3B of APAs expected to be deferred to 2024)

Expected additional sales for 2H deliveries

United States

Commercial contracts signed

- Retail pharmacies
- Wholesalers and distributors
- Group purchasing organizations
- IDNs and health systems
- U.S. government entities (CDC, VA, etc.)
- Employers and other providers

~$2-4B

moderna

U.S. Fall 2023 COVID-19 market size is dependent on vaccination rates

Parameters informing 2023 COVID-19 volume forecast



1. Average over past 9 years
2. https://www.health.gov.au/resources/publications/covid-19-vaccine-rollout-update-21-july-2023?language=en

moderna

2023 Fall vaccine campaign focused on increasing market doses administered and solidifying Moderna's market share



moderna

Strong product profile for expected RSV 2024 launch

Only mRNA RSV investigational vaccine with positive Phase 3 data

High efficacy across vulnerable and older populations[1]

83.7% efficacy in overall study population

88.4% efficacy in participants with comorbidities

95.4% efficacy in participants aged 70-79 years

Well-established safety and tolerability profile for mRNA vaccine technology

- Over 1 billion COVID-19 doses using same mRNA technology
- Most solicited adverse reactions were mild to moderate[1,2]
- No cases of Guillain-Barre Syndrome (GBS) have been reported with mRNA-1345 in Phase 3 RSV trial[2]



Ease of administration

- Single-dose prefilled syringe
- HCP customer convenience: only ready-to-use formulation, saving time and reducing administration errors[3,4]

1 Based of RSV LRTD with ≥2 symptoms; RSVVW data
2 As of April 30, 2023
3 www.ncbi.nlm.nih.gov/pmc/articles/PMC7846520/
4 www.ncbi.nlm.nih.gov/pmc/articles/PMC7913196/

moderna

2Q23 earnings call agenda

Business Review
Stéphane Bancel, CEO

R&D/Clinical Programs
Stephen Hoge, M.D., President

Commercial Market
Arpa Garay, CCO

Financials
Jamey Mock, CFO

Looking Forward
Stéphane Bancel, CEO

Second quarter 2023 financial results

In $ millions, except per share amounts	2Q 2023	2Q 2022	Change (2Q23 vs. 2Q22)	
Product sales	**$ 293**	**$ 4,531**	**$ (4,238)**	**(94)%**
Other revenue[1]	51	218	(167)	(77) %
Total revenue	**344**	**4,749**	**(4,405)**	**(93)%**
Cost of sales	731	1,381	(650)	(47) %
Research and development	1,148	710	438	62 %
Selling, general and administrative	332	211	121	57 %
Total operating expenses	**2,211**	**2,302**	**(91)**	**(4)%**
(Loss) income from operations	**(1,867)**	**2,447**	**(4,314)**	**(176)%**
Other income, net	118	27	91	337 %
(Benefit from) provision for income taxes	(369)	277	(646)	(233) %
Net (loss) income	**$ (1,380)**	**$ 2,197**	**$ (3,577)**	**(163)%**
(Loss) earnings per share – Diluted	$ (3.62)	$ 5.24	$ (8.86)	(169) %
Weighted average shares – Diluted[2]	381	419	(38)	(9) %
Weighted average shares – Basic[2]	381	396	(15)	(4) %
Effective tax rate	21 %	11 %		

[1]Includes grant revenue and collaboration revenue

[2]We generated a net loss in 2Q 2023, therefore the basic and diluted weighted average shares calculation was the same

moderna

Cash / investments and cash deposits

Cash / investments

In USD Billions

Cash, cash equivalents and investments



Cash, cash equivalents and investments as of June 30, 2023, at $14.6 billion, down from $16.4 billion as of March 31, 2023

Balance of cash deposits for future product supply



Balance of cash deposits for future product supply as of June 30, 2023, at $1.7 billion, below prior quarter driven by product deliveries against customer deposits

Cash and investments decreased in 2Q, primarily driven by the operating loss and share buyback activity

moderna

Moderna's capital allocation priorities

Reinvest in the business and accelerate investment in R&D, manufacturing infrastructure and company buildout



- Phase 3 trials: COVID boosters, Flu, RSV, CMV, Next-gen COVID-19, INT
- Individualized Neoantigen Therapy
- 47 development programs

Seek attractive external investment opportunities (licenses and/or M&A) to further expand the reach of Moderna's technology

life edit an elevatebio company · generation bio · OriCiro · CytomX Therapeutics

Return capital to shareholders

- Repurchased 4.4 million shares in 2Q 2023 for $0.6 billion
- Repurchased 8.0 million shares year-to-date for $1.2 billion
- $1.7 billion remaining capacity under the $3.0 billion August 2022 authorization as of June 30, 2023

moderna

2023 updated financial framework

Sales	• Expecting 2023 COVID-19 sales of $6-8 billion, dependent on U.S. vaccination rates • 2H23 sales timing subject to regulatory approvals; currently expecting sales split of ~30% in Q3; 70% in Q4
Cost of sales	• Now expect FY 2023 reported cost of sales to be ~$3.5-4.0 billion for the year
R&D & SG&A Expenses	• Continue to expect full year R&D and SG&A expenses of ~$6 billion, with ~$4.5 billion in R&D
Tax	• We now anticipate a full year tax benefit of ~$0.7-1.0 billion, driven by an assumed operating loss, R&D credits, international provisions and non-recurring items
Capital Expenditures	• Continue to expect capital expenditures of ~$1.0 billion

moderna

2Q23 earnings call agenda

Business Review
Stéphane Bancel, CEO

R&D/Clinical Programs
Stephen Hoge, M.D., President

Commercial Market
Arpa Garay, CCO

Financials
Jamey Mock, CFO



Looking Forward
Stéphane Bancel, CEO

Commercial outlook

COVID-19 sales

- Commercial contracts in place across U.S. customer segments
- Expecting 2023 COVID-19 sales in the range of $6-8 billion

RSV

- Anticipate RSV commercial launch in 2024
- Strong RSV product profile with pre-filled syringe at launch

Individualized Neoantigen Therapy

- Comprehensive plan to expand manufacturing scale while reducing needle-to-needle time frames
- Working with our partner Merck to assess prioritization beyond melanoma and non-small cell lung cancer (NSCLC)

Moderna is preparing to launch a number of new products in 2024 through 2026

Up to 5 respiratory vaccines

- RSV
- Seasonal Flu
- Combination vaccines
- Next-gen COVID-19
- Next-gen Flu

Our first latent virus vaccine

- CMV

Our first oncology product and multiple rare disease medicines

- INT in multiple indications
- MMA
- PA

Our mRNA platform is poised to deliver multiple commercial products

*Subject to clinical and regulatory success

moderna

Save the Date

Events in 2023

- **R&D Day**
  September 13th
- **ESG Day**
  December 7th

moderna

Our Mission

Deliver the greatest possible impact to people through mRNA medicines.



moderna

Thank you

Q&A



moderna

Moderna's Respiratory Vaccines (Pipeline 1/3)

Modality	Program	ID #	Preclinical development	Phase 1	Phase 2	Phase 3	Commercial	Moderna rights
Adults	COVID-19 vaccine	**Spikevax®**						Worldwide
		mRNA-1283	Next generation (2-5 °C)					Worldwide
	Flu vaccine	**mRNA-1010**						Worldwide
		mRNA-1020						Worldwide
		mRNA-1030						Worldwide
		mRNA-1011						Worldwide
		mRNA-1012						Worldwide
Infectious disease vaccines	Older adults RSV vaccine	**mRNA-1345**						Worldwide
	COVID + Flu vaccine	**mRNA-1073**						Worldwide
	COVID + Flu vaccine	**mRNA-1083**						Worldwide
	COVID + Flu + RSV vaccine	**mRNA-1230**						Worldwide
	Flu + RSV vaccine	**mRNA-1045**						Worldwide
	Endemic HCoV vaccine	**mRNA-1287**						Worldwide
	Pandemic Flu	**mRNA-1018**						Worldwide
Adolescents & Pediatrics	COVID-19 vaccine (adolescents)	**mRNA-1273.222/.214**	TeenCOVE					Worldwide
	COVID-19 vaccine (pediatrics)	**mRNA-1273.222/.214**	KidCOVE					Worldwide
	Pediatric RSV vaccine	**mRNA-1345**						Worldwide
	Pediatric hMPV + PIV3 vaccine	**mRNA-1653**						Worldwide
	Pediatric RSV + hMPV vaccine	**mRNA-1365**						Worldwide

Moderna's Latent & Emerging Vaccines (Pipeline 2/3)

Modality	Program	ID #	Preclinical development	Phase 1	Phase 2	Phase 3	Commercial	Moderna rights
Latent  Infectious disease vaccines	CMV vaccine	**mRNA-1647**						Worldwide
	EBV vaccine *(to prevent infectious mononucleosis)*	**mRNA-1189**						Worldwide
	EBV vaccine *(to address EBV sequelae)*	**mRNA-1195**						Worldwide
	HSV vaccine	**mRNA-1608**						Worldwide
	VZV vaccine	**mRNA-1468**						Worldwide
	HIV vaccines	**mRNA-1644**						Worldwide ***IAVI** funded*
		mRNA-1574						Worldwide ***IAVI/others** funded*
Enteric	Norovirus vaccines	**mRNA-1403**						Worldwide
		mRNA-1405						Worldwide
Bacterial	Lyme vaccines	**mRNA-1975**						Worldwide
		mRNA-1982						Worldwide
Public health	Zika vaccine	**mRNA-1893**						Worldwide ***BARDA** funded*
	Nipah vaccine	**mRNA-1215**						Worldwide ***NIH** funded*

moderna

Moderna's Therapeutics (Pipeline 3/3)

Modality	Program	ID #	Preclinical development	Phase 1	Phase 2	Phase 3	Commercial	Moderna rights
Systemic secreted & cell surface therapeutics	Relaxin *Heart failure*	**mRNA-0184**						Worldwide
	PD-L1 *Autoimmune hepatitis*	**mRNA-6981**						Worldwide
Cancer vaccines & therapeutics	Individualized neoantigen therapy (INT)	**mRNA-4157**						50-50 global profit sharing with **Merck**
	KRAS vaccine	**mRNA-5671**						Worldwide
	Checkpoint vaccine	**mRNA-4359**						Worldwide
Intratumoral Immuno-oncology	OX40L/IL-23/IL-36γ (Triplet) *Solid tumors/lymphoma*	**mRNA-2752**						Worldwide
	IL-12 *Solid tumors*	**MEDI1191**						Worldwide
Localized regenerative therapeutics	VEGF-A *Myocardial ischemia*	**AZD8601**						Worldwide
	Propionic acidemia (PA)	**mRNA-3927**						Worldwide
	Methylmalonic acidemia (MMA)	**mRNA-3705**						Worldwide
Systemic intracellular therapeutics	Glycogen storage disease type 1a (GSD1a)	**mRNA-3745**						Worldwide
	Ornithine transcarbamylase deficiency (OTC)	**mRNA-3139**						Worldwide
	Phenylketonuria (PKU)	**mRNA-3283**						Worldwide
Inhaled pulmonary therapeutics	Crigler-Najjar syndrome type 1 (CN-1)	**mRNA-3351**						Provided to **ILCM** free of charge
	Cystic fibrosis (CF)	**VX-522**						**Vertex** to pay milestones and royalties

Anticipated pipeline milestones in 2023

COVID-19 vaccines

sBLA approval/authorization of new XBB.1.5 vaccine; ACIP Fall booster recommendations

Flu vaccines

mRNA-1010 P303 update in 3Q

RSV vaccine

Complete FDA rolling submission in 3Q with priority review voucher (PRV)

CMV vaccine

Complete Phase 3 CMVictory study enrollment

Individualized Neoantigen Therapy (INT)

Expand development program to additional tumor types, including NSCLC

PA

Advance PA program to dose expansion

moderna